Subtype
Gastroesophageal Junction Adenocarcinoma
CI-CAN-00005403Explore in graph →
228 active trials9 approved drugs25 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005403Explore in graph →
Clinical trials
695 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (82)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06203600 | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | recruiting | Phase 2 / Phase 3 | 224 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07529808 | Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 164 | BigHat Biosciences, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07603375 | Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma(TNT Esophagus) | recruiting | Phase 2 | 60 | Duke UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07392892 | Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer | recruiting | Phase 2 / Phase 3 | 840 | PfizerINDUSTRY | 10 | Sep 28, 2026 | clinicaltrials |
| NCT06005493 | Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 392 | AstraZenecaINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT06047379 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | recruiting | Phase 1 / Phase 2 | 134 | Neonc Technologies, Inc.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06123338 | A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer | recruiting | Phase 2 | 49 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06253650 | Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease(TRINITY) | recruiting | Phase 2 | 46 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06324357 | Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | recruiting | Phase 1 / Phase 2 | 768 | Boehringer IngelheimINDUSTRY | 10 | Sep 16, 2026 | clinicaltrials |
| NCT06730373 | First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) | recruiting | Phase 2 | 110 | Qilu Hospital of Shandong UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06732388 | Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus | recruiting | Phase 2 | 76 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07818018 | A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07000253 | Timing of Comprehensive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma(OMEC-5) | recruiting | Phase 2 | 290 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 3 | Sep 10, 2026 | clinicaltrials |
| NCT07282912 | Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels(OLIGOMETS) | recruiting | Phase 2 | 54 | Yale UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07001748 | Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity(STOPGAP II) | recruiting | Phase 2 / Phase 3 | 148 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07222657 | Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma | recruiting | Phase 2 | 40 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04939051 | Obeticholic Acid for Prevention in Barrett's Esophagus | recruiting | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07699939 | Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma(PLATANUS) | recruiting | Phase 2 | 136 | National Cancer Center, JapanOTHER_GOV | 2 | Aug 5, 2026 | clinicaltrials |
| NCT07464756 | SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer | recruiting | Phase 2 | 80 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04840264 | Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction | recruiting | Phase 2 | 79 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07689851 | Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer | recruiting | Phase 2 | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04114136 | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | recruiting | Phase 2 | 72 | Dan ZandbergOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06038578 | A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer | recruiting | Phase 2 | 146 | Toray Industries, IncINDUSTRY | 3 | Jun 23, 2026 | clinicaltrials |
| NCT07655024 | TAIC FOLFOX for Locally Advanced G/GEJA(TFLAG) | recruiting | Phase 2 | 31 | Guang'anmen Hospital of China Academy of Chinese Medical SciencesOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05977998 | A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07432295 | Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) | recruiting | Phase 2 | 180 | I-Mab Biopharma US LimitedINDUSTRY | 3 | May 14, 2026 | clinicaltrials |
| NCT07007182 | Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer | recruiting | Phase 2 | 54 | Jinbo YueOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07178808 | PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER | recruiting | Phase 2 | 30 | Banner HealthOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06846346 | Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma(GRACIE) | recruiting | Phase 2 | 88 | UNICANCEROTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07551362 | Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer(DUET-GEJ) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07353684 | Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer | recruiting | Phase 2 | 49 | Beijing Friendship HospitalOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07223424 | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy(PSI-Immune) | recruiting | Phase 2 | 880 | Diwakar DavarOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03161522 | Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05745857 | Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas(SLURP) | recruiting | Phase 2 | 25 | University Medical Center GroningenOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05927857 | Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer . | recruiting | Phase 1 / Phase 2 | 45 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05753306 | Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study | recruiting | Phase 2 | 40 | Mayo ClinicOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06461910 | Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 2 | 30 | Zekuan XuOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT03539822 | Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies(CAMILLA) | recruiting | Phase 1 / Phase 2 | 117 | Anwaar SaeedOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07334431 | Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer | recruiting | Phase 1 / Phase 2 | 45 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07311408 | SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure(SHR-2554) | recruiting | Phase 2 | 40 | Jingdong ZhangOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06161818 | Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction(TNT-OES-2) | recruiting | Phase 2 | 216 | Erasmus Medical CenterOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07289997 | Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC) | recruiting | Phase 2 | 39 | Hebei Medical University Fourth HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07263386 | A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer(ARTEMIS-GC3) | recruiting | Phase 2 | 460 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06333314 | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI(Pan-MSI-ACSE) | recruiting | Phase 2 | 120 | UNICANCEROTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT04656041 | Folfox+Irinotecan+Chemort In Esophageal Cancer | recruiting | Phase 2 | 40 | Massachusetts General HospitalOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT05563766 | A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer | recruiting | Phase 2 | 78 | VA Office of Research and DevelopmentFED | 1 | Nov 5, 2025 | clinicaltrials |
Data updated 18 hours agoSource updated Sep 29, 2026source: clinicaltrials